Amylin research before a treatment decision
Cagrilintide doctor:
start with the
right questions.
You can ask about a drug without deciding to take it. Start with what is known. Then make space for your own health, your budget, and your questions.
Begin with the drugThe starting point
What is cagrilintide, really?
Cagrilintide is a lab-made drug under study for weight loss. It is an altered copy of amylin, a hormone, or body signal, that helps with feeling full.
It is a peptide: a small string of protein building blocks. Calling a product a “peptide” says nothing about its safety or legal status.
CagriSema combines cagrilintide with a second medicine, semaglutide. Semaglutide is the ingredient in the brands Ozempic and Wegovy. The drug cagrilintide and the combination CagriSema are different things.
Semaglutide is a lab-made version of a body signal. It helps you feel full and helps your body handle sugar.
The amylin description comes from the research published in The Lancet.
Read the cagrilintide study summaryWhat does “approved” mean?
Medicine review in the US is the job of the Food and Drug Administration (FDA). Approval means it has reviewed a specific product's evidence for a specific use.
As of 28 September 2026, the FDA was reviewing CagriSema for weight loss and keeping weight off in adults. An application is a request for approval, not a decision.
That request covers CagriSema, not cagrilintide on its own. As of 28 September 2026, cagrilintide alone was still being tested for weight loss in people.
Being in these later studies does not give the drug an approval date.
Public records checked on 28 September 2026 showed volunteers getting cagrilintide in studies at US sites. The FDA oversees this research.
A study overseen by the FDA is not the same as an FDA-approved medicine for usual care.
For a different care discussion, semaglutide sold as Wegovy had US approval for weight loss as of 26 September 2026.
A useful visit can begin with your health goals and the options that fit them. You can come to the visit with questions before choosing any drug.
Read Wegovy's official use informationThe study results need context
REDEFINE 1 was a trial, a study that tests a treatment in people. The New England Journal of Medicine reported its results in adults without diabetes over 68 weeks.
The CagriSema group lost 20.4% of their starting body weight on average. This result counts everyone assigned to that group, including people who stopped taking the drug. It describes the whole group, rather than just those who stayed on treatment. The placebo group, given a dummy treatment, lost 3.0% on average.
People also had support with food and activity habits, and the drug's maker funded the study.
Those results concern the combination, not cagrilintide alone. A group average cannot tell you what would happen to you.
Read the trial reportThe care search
Look for a health review, then check the person.
Possible starting points include an in-person clinic or online care with a doctor who holds a state licence. Telehealth means a health visit by screen, phone, or an online exchange.
A licence is the state's permission for a doctor to practise medicine.
Ask whether the service reviews weight concerns and can discuss options beyond the drug in your search. Ask who answers your questions between visits and how to reach the person prescribing your medicine.
US health department guidance checked in September 2026 says a doctor needs permission to practise in the state you are in during your visit.
State rules for remote prescribing differ, as of September 2026. Ask about the rules for your location, including when an in-person visit is needed.
Read the health department's licence guidanceCheck a doctor's licence
Request the doctor's full name and licence number. Follow the link below to your state's medical board. Enter the name or number in that board's search. Check that the record names the same doctor and shows a current licence.
Licensing doctors is the job of state medical boards. Their records show licences and official penalties or charges against doctors. Links to these boards' websites come from their shared group, the Federation of State Medical Boards.
A charge is an accusation that may still be awaiting a decision. What each board makes public varies by state. A record without any reported charge or penalty cannot establish the quality of a doctor's care.
Find the board for your stateCheck the pharmacy separately
For any medicine discussed, ask for the actual pharmacy's name. Open the FDA link below, choose your state, then enter the pharmacy's name in the state's search. Keep the answer with your visit notes.
The FDA's pharmacy lookup page links to each state's searchable list of pharmacy licences. Finding a licence confirms the licence, not that every medicine offered is appropriate.
Find your state's pharmacy licence searchWhat a visit can involve
Write down your health goals, past treatment, medicines, and questions. Ask how the person prescribing will review them. Ask what happens if the answer is that no medicine fits.
The medical boards' guidance says a doctor must deal with tests or an examination needed to assess your health. The doctor can do the checks, arrange for them, or send you to someone able to carry them out.
Ask which checks are needed before a treatment decision, where they will happen, and who will review the results.
This describes the standard of care: the care a doctor is expected to provide. It is guidance for state boards, not a promise that every service follows it.
Read the boards' expectations for remote careCost notes
Get the whole cost in writing.
Cagrilintide and CagriSema had no official US product price as of 28 September 2026, because neither had an approved product.
An online cagrilintide price is not the price of an approved medicine, based on that September 2026 status.
For online weight care, the medicine bill may be separate from a monthly fee to use the service, often called a membership. Most of the service prices recorded in September 2026 had this structure.
Ask what the monthly fee pays for: visits, messages, follow-up, or something else. Before paying for a health review, request a written total. Ask about the visit, any fee that repeats each month, tests, medicine, delivery, and follow-up. Ask what is charged if nothing is prescribed.
Beyond a cagrilintide price tag
“Once the opening offer ends, how much will I pay, and what does that sum cover?”
If the conversation moves to another medicine
Ask your insurance plan about the specific medicine being prescribed and the reason for that prescription. Request the amount you would pay and ask whether the plan must agree to pay before you fill the prescription.
As of September 2026, some weight medicines could receive coverage from Medicare drug plans for other accepted uses, such as diabetes. That means a plan is allowed to pay, not that your plan has agreed to pay. Coverage still depends on your plan's list of medicines and its approval rules.
Ask the plan: “Will you pay toward this medicine for my condition, and what would my share of the bill be?”
GLP-1 is a body signal involved in appetite. Semaglutide is an altered copy of it.
Medicare's temporary GLP-1 Bridge program covers certain weight medicines. As of 26 September 2026, eligible people paid $50 for a monthly supply. This is the copay, meaning their part of the bill.
Cagrilintide and CagriSema were not among its covered products as of 26 September 2026.
Under the September 2026 rules, the Bridge program requires you to be at least 18 and to have an accepted Medicare drug plan. That can be a separate drug plan, called Part D, or certain Medicare Advantage plans that include drug coverage.
The health rules use body mass index (BMI), which scores weight in relation to height. With a BMI of at least 35, the weight rule is met even without another health condition.
With a BMI of 30 or above, you need one of three conditions: kidney disease, high blood pressure that is difficult to control, or certain heart failure. The heart failure must be the type where the heart pumps out a normal share of the blood it holds. Even with two blood pressure medicines, the reading must remain above 140 (top number) or above 90 (bottom number). For kidney disease, the required stage is 3a or worse; the stage measures loss of kidney function.
With a BMI of 27 or above, the listed conditions include artery disease with limb symptoms, pre-diabetes, or a past heart attack or stroke. Pre-diabetes means blood sugar is higher than normal but below the diabetes range.
Type 2 diabetes excludes you from this $50 program under the September 2026 rules. A prescription for diabetes goes through your own Medicare drug plan, with that plan's costs and payment rules.
The Bridge also excludes moderate or severe sleep apnea, a condition where breathing pauses during sleep. A certain fatty liver disease with substantial scarring is excluded too. That does not mean every fatty liver diagnosis rules you out. You cannot use the Bridge during 2026 if your Part D plan paid for a GLP-1 medicine in 2026.
These are key rules; the Medicare page below has the full terms. Ask your doctor to check your health details against them. Ask your plan to confirm that your exact plan type is accepted before counting on the price.
See the Medicare program and its termsCagrilintide offers under the lens
What deserves a closer look?
A “compounded” cagrilintide offer
Compounding means making a medicine to order, usually in a pharmacy.
As of 26 September 2026, the FDA stated that federal law did not permit cagrilintide in compounding.
FDA approval is also absent for a compounded product. As of September 2026, the agency did not review a compounded product's safety, effectiveness, or manufacturing quality before sale.
Read the FDA's explanation of compoundingA research label presented as treatment
In a March 2026 warning letter, the FDA said one seller was offering cagrilintide as a drug for people. Its labels said “laboratory research purposes only” and “not for human consumption.” The FDA said those words did not change what the seller was offering.
This was the agency's accusation about one business, not a court's final decision.
If someone calls an offer a study, ask for its NCT number. This is the study's lookup number on ClinicalTrials.gov, the US government's study website. It begins with the letters NCT.
Enter that number in the website's search to find the study's own page.
Finding a study page does not prove that the person offering you a place works with that study.
Look for the study team's contact details on its page. Use any listed details to ask that team whether the person offering you a place works with them.
Look up a study on the government's websiteA claim that the studies settle every concern
The REDEFINE 1 report described stomach and bowel side effects as common with CagriSema. Most were temporary and mild to moderate.
The study of cagrilintide alone, published in The Lancet, also reported feeling sick, trouble passing stools, loose stools, and reactions where the shot went in.
As of 28 September 2026, neither cagrilintide nor CagriSema had an FDA label, the official information about a medicine's use. There was no FDA-reviewed text explaining use in pregnancy or effects on other medicines.
Bring pregnancy plans, past health problems, and your medicine list into any care discussion. Ask about the evidence for the specific product in that conversation.
See the benefits and harms in the same reportA prescription with no room for questions
In its guidance checked in September 2026, the medical boards' federation said a choice from a medicine list cannot, on its own, meet the requirements for proper care. For example, an online form might ask you to pick a drug. That choice alone does not replace a review of your health.
The guidance also called for a way for patients to ask their own follow-up questions.
Read the guidance on checking health before prescribingFor your visit
You can start with these words.
Save the questions that fit your concern. Leave room to write the answers in your own words.
“What options fit my health goals, and why?”
“What is the exact medicine, and who makes it?”
“What needs checking before we decide?”
“What would follow-up look like, and who answers questions?”
“What is the full cost, including anything billed separately?”
“If this option does not fit, what else can we discuss?”
There is room for “I need a clearer explanation.” A useful next step can be a better conversation.
Follow the sources
Use the record that answers your question.
For approval and compounding, follow the FDA links beside those answers. For a doctor's licence, use the state board. For study results, read the linked journal summary.
The dates beside the answers matter. Check the source again when you discuss care; an older search result cannot settle a new decision.
Keep a text copy of these field notes